Advancing novel bispecific antibodies and antibody-drug conjugates to treat cancer.
Leveraging our technology, unique insights and capabilities to develop bispecifics and ADCs with superior profiles.
We are developing programs to address specific issues in currently available therapies and overcome major hurdles in novel classes of molecules.
Our team’s expertise and insights position us well to usher in a new wave of novel bispecific antibody and ADC therapies.